Literature DB >> 22330751

Engineering therapies in the CNS: what works and what can be translated.

Andrew J Shoffstall1, Dawn M Taylor, Erin B Lavik.   

Abstract

Engineering is the art of taking what we know and using it to solve problems. As engineers, we build tool chests of approaches; we attempt to learn as much as possible about the problem at hand, and then we design, build, and test our approaches to see how they impact the system. The challenge of applying this approach to the central nervous system (CNS) is that we often do not know the details of what is needed from the biological side. New therapeutic options for treating the CNS range from new biomaterials to make scaffolds, to novel drug-delivery techniques, to functional electrical stimulation. However, the reality is that translating these new therapies and making them widely available to patients requires collaborations between scientists, engineers, clinicians, and patients to have the greatest chance of success. Here we discuss a variety of new treatment strategies and explore the pragmatic challenges involved with engineering therapies in the CNS.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22330751      PMCID: PMC3377833          DOI: 10.1016/j.neulet.2012.01.058

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  135 in total

Review 1.  Tissue cells feel and respond to the stiffness of their substrate.

Authors:  Dennis E Discher; Paul Janmey; Yu-Li Wang
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

2.  Channelrhodopsin-2 gene transduced into retinal ganglion cells restores functional vision in genetically blind rats.

Authors:  Hiroshi Tomita; Eriko Sugano; Hitomi Isago; Teru Hiroi; Zhuo Wang; Emi Ohta; Makoto Tamai
Journal:  Exp Eye Res       Date:  2009-12-27       Impact factor: 3.467

3.  Heparin-binding-affinity-based delivery systems releasing nerve growth factor enhance sciatic nerve regeneration.

Authors:  Matthew D Wood; Daniel Hunter; Susan E Mackinnon; Shelly E Sakiyama-Elbert
Journal:  J Biomater Sci Polym Ed       Date:  2010       Impact factor: 3.517

4.  Spinal cord reconstruction using NeuroGel implants and functional recovery after chronic injury.

Authors:  S Woerly; V D Doan; F Evans-Martin; C G Paramore; J D Peduzzi
Journal:  J Neurosci Res       Date:  2001-12-15       Impact factor: 4.164

5.  Tuning supramolecular rigidity of peptide fibers through molecular structure.

Authors:  E Thomas Pashuck; Honggang Cui; Samuel I Stupp
Journal:  J Am Chem Soc       Date:  2010-05-05       Impact factor: 15.419

6.  The epidemiology and impact of traumatic brain injury: a brief overview.

Authors:  Jean A Langlois; Wesley Rutland-Brown; Marlena M Wald
Journal:  J Head Trauma Rehabil       Date:  2006 Sep-Oct       Impact factor: 2.710

7.  Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth.

Authors:  Justin S Golub; Young-tae Kim; Craig L Duvall; Ravi V Bellamkonda; Divya Gupta; Angela S Lin; Daiana Weiss; W Robert Taylor; Robert E Guldberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-03-12       Impact factor: 4.733

8.  Neural precursors express multiple chondroitin sulfate proteoglycans, including the lectican family.

Authors:  Peter Kabos; Harry Matundan; Mandana Zandian; Cristina Bertolotto; Michael L Robinson; Brian E Davy; John S Yu; Richard C Krueger
Journal:  Biochem Biophys Res Commun       Date:  2004-06-11       Impact factor: 3.575

9.  Viability and differentiation of neural precursors on hyaluronic acid hydrogel scaffold.

Authors:  Linjie Pan; Yongjuan Ren; Fuzhai Cui; Qunyuan Xu
Journal:  J Neurosci Res       Date:  2009-11-01       Impact factor: 4.164

10.  Ex vivo VEGF delivery by neural stem cells enhances proliferation of glial progenitors, angiogenesis, and tissue sparing after spinal cord injury.

Authors:  Hyuk Min Kim; Dong Hoon Hwang; Jong Eun Lee; Seung U Kim; Byung G Kim
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240

View more
  2 in total

Review 1.  Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models.

Authors:  Mariana R Carvalho; Daniela Lima; Rui L Reis; Joaquim M Oliveira; Vitor M Correlo
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

Review 2.  Carriers in cell-based therapies for neurological disorders.

Authors:  Francisca S Y Wong; Barbara P Chan; Amy C Y Lo
Journal:  Int J Mol Sci       Date:  2014-06-13       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.